Loading…
Medpace Holdings, Inc.
Medpace Holdings, Inc. (MEDP) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Cincinnati, United States and has 6,500 employees. The company is worth $18.25B and trades at 36.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.53B in fiscal 2025, up 20.0% from the year before. Net income was $451.12M. The share price is 4.5% below its 52-week high of $684.52. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $677.31M. In that quarter, 5 of them reduced the position. Over the last 30 days, company insiders sold $59.31M of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Articles on this site that cover Medpace Holdings, Inc..
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +198.2% over 5Y.
today you would have $2,729.95▲ +173.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $561.65 | $332.23 | $306.53 | $212.41 | $217.64 | $139.20 | $84.06 | $52.93 | $36.26 | $36.07 | |
| P/E | 35.4x | 36.8x | 26.3x | 34.5x | 29.2x | 45.2x | 36.2x | 31.5x | 26.9x | 37.0x | 97.5x |
| P/S | 4.7x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 35.4 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZBHZimmer Biomet Holdings Inc | $98.81 | 24.0x | 1.5x | 0.97% | 6.41% | $18.85B |
| RVTYRevvity Inc | $157.36 | 74.9x | 2.4x | 0.18% | 3.21% | $17.56B |
| CRLCharles River Laboratories International Inc | $339.66 | — | 5.7x | 0.00% | -7.52% | $16.36B |
| EXELExelixis Inc | $65.31 |
| 6.3x |
| 4.8x |
| 5.0x |
| 4.5x |
| 6.7x |
| 5.4x |
| 3.5x |
| 2.7x |
| 3.0x |
| 3.5x |
| P/B | 7.1x | 34.7x | 12.3x | 16.9x | 17.1x | 8.0x | 6.2x | 4.2x | 3.2x | 2.5x | 2.4x |
| EPS | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 | $2.67 | $1.97 | $0.98 | $0.37 |
| Profit margin | 15.35% | 17.83% | 19.17% | 15.00% | 16.81% | 15.92% | 15.70% | 11.67% | 10.39% | 8.97% | 3.18% |
| ROE | 18.56% | 98.27% | 48.98% | 50.60% | 63.50% | 19.08% | 18.04% | 13.83% | 12.22% | 7.68% | 2.20% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-21.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 20.4x |
| 8.8x |
| 0.00% |
| 44.39% |
| $16.18B |
| INSMINSMED Inc | $95.06 | — | 27.4x | 0.00% | -87.22% | $20.76B |
| ASNDAscendis Pharma A/S | $242.99 | 18.6x | 9.9x | 0.00% | 118.78% | $15.99B |